Given that disease-modifying drugs are currently emerging to treat this rare genetic disease, a better understanding of the clinical presentation and evolution of SOD1 ALS is crucial to enhance prognosis stratification in upcoming clinical trials [10,11]. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.